The current standard of care for prostate cancer can sometimes cease to be effective, causing the cancer to worsen. The TRITON2 and TRITON3 studies are looking at the PARP inhibitor, rucaparib, in the treatment of prostate cancer with BRCA1 and BRCA2 mutations. In addition, the TRITON trials are employing the use of genomic screening of plasma, which can provide valuable information as it is often difficult to obtain biopsies in patients with prostate cancer. At ESMO 2018, Dr Josep M Piulats talked to us about the TRITON studies, how the preliminary data are already helping select patients who will benefit from rucaparib, how these trials will affect clinical practice, and future research.
1. Could you tell us a little about the mechanism of action of rucaparib and the rationale for using it in the treatment of metastatic castration-resistant prostate cancer? (0:11)
2. What have been the major findings from the data of the TRITON2 study? (1:36)
3. What were the findings of your recent study involving genomic screening of plasma ctDNA and tissue samples in TRITON2 and TRITON3? (2:37)
4. What are the clinical implications of these findings? (3:49)
5. What are the next steps in this area of research over the coming years? (4:56)
Speaker disclosures: Josep M Piulats has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Prostate Cancer
Fred Saad, ESMO 2022: Highlights in prostate cancer – Phase 3 trials in the STAMPEDE platform protocol
Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss clinical trial highlights in prostate cancer presented at EMSO 2022. He highlights the results from one of the phase 3 STAMPEDE trials, investigating combination abiraterone and enzalutamide or abiraterone and prednisolone, for metastatic hormone sensitive prostate cancer (mHSPC), […]
Fred Saad, ESMO 2022: Phase 3 PROpel trial of abiraterone and olaparib for patients with prostate cancer – Biomarker analysis and updated results
In the PROpel trial, abiraterone and olaparib significantly prolonged radiographic progression free survival in patients with metastatic castration-resistant prostate cancer. Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss the biomarker analysis from the primary analysis, and updated overall survival and safety data. The abstract entitled ‘Biomarker […]
Axel Merseburger, ASCO 2022: Highlights in prostate cancer clinical trials – Phase 3 SHR3680 trial, ENZAMET trial, MAGNITUDE trial, PROPEL trial, phase 2 lutetium 177 trial, VISION trial
ASCO 2022 showcased many important studies in prostate cancer. Prof. Axel Merseburger (Department of Urology, University of Lubeck, Germany), touchONCOLOGY’s Editor-in-Chief, joins us to share his highlights. In this interview he discusses: the phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy in patients with prostate cancer (0:40); the interim overall […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!